Alps Advisors Inc. Sells 8,751 Shares of Flexion Therapeutics Inc (FLXN)

Alps Advisors Inc. decreased its holdings in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) by 17.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,599 shares of the specialty pharmaceutical company’s stock after selling 8,751 shares during the quarter. Alps Advisors Inc.’s holdings in Flexion Therapeutics were worth $1,042,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of FLXN. Rubric Capital Management LP lifted its holdings in Flexion Therapeutics by 108.6% in the 1st quarter. Rubric Capital Management LP now owns 2,023,704 shares of the specialty pharmaceutical company’s stock worth $45,351,000 after buying an additional 1,053,704 shares in the last quarter. Millennium Management LLC acquired a new position in Flexion Therapeutics in the 1st quarter worth $15,511,000. Peregrine Capital Management LLC lifted its holdings in Flexion Therapeutics by 5.4% in the 2nd quarter. Peregrine Capital Management LLC now owns 666,160 shares of the specialty pharmaceutical company’s stock worth $17,220,000 after buying an additional 33,890 shares in the last quarter. Northern Trust Corp lifted its holdings in Flexion Therapeutics by 1.3% in the 1st quarter. Northern Trust Corp now owns 426,469 shares of the specialty pharmaceutical company’s stock worth $9,558,000 after buying an additional 5,451 shares in the last quarter. Finally, UBS Group AG lifted its holdings in Flexion Therapeutics by 299.1% in the 1st quarter. UBS Group AG now owns 176,511 shares of the specialty pharmaceutical company’s stock worth $3,956,000 after buying an additional 132,279 shares in the last quarter. Institutional investors and hedge funds own 98.22% of the company’s stock.

Shares of Flexion Therapeutics stock opened at $21.91 on Friday. The stock has a market capitalization of $868.25 million, a PE ratio of -5.27 and a beta of 0.76. The company has a current ratio of 12.90, a quick ratio of 12.78 and a debt-to-equity ratio of 0.80. Flexion Therapeutics Inc has a 1 year low of $19.06 and a 1 year high of $32.25.

Flexion Therapeutics (NASDAQ:FLXN) last issued its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.06. The company had revenue of $3.80 million during the quarter, compared to analyst estimates of $3.96 million. sell-side analysts forecast that Flexion Therapeutics Inc will post -4.75 earnings per share for the current year.

In other Flexion Therapeutics news, CEO Michael D. Clayman acquired 10,000 shares of the stock in a transaction that occurred on Thursday, August 9th. The stock was acquired at an average price of $22.33 per share, with a total value of $223,300.00. Following the transaction, the chief executive officer now directly owns 75,282 shares in the company, valued at $1,681,047.06. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Neil Bodick sold 50,000 shares of the business’s stock in a transaction dated Tuesday, July 3rd. The shares were sold at an average price of $25.07, for a total transaction of $1,253,500.00. The disclosure for this sale can be found here. Corporate insiders own 14.59% of the company’s stock.

A number of equities analysts have commented on FLXN shares. ValuEngine upgraded shares of Flexion Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, April 27th. BidaskClub upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, April 27th. Wells Fargo & Co restated a “buy” rating on shares of Flexion Therapeutics in a research note on Thursday, April 26th. Zacks Investment Research upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, May 11th. Finally, Benchmark began coverage on shares of Flexion Therapeutics in a research note on Thursday, June 28th. They issued a “buy” rating and a $39.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $91.50.

Flexion Therapeutics Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply